spondyloarthropathy: A group of inflammatory rheumatic diseases associated with arthritis and enthesitis, and often involving the axial skeleton. The most common form of spondyloarthritis is ankylosing spondylitis. Other forms include axial spondyloarthritis, peripheral spondyloarthritis, reactive arthritis, psoriatic arthritis/spondylitis and enteropathic arthritis/spondylitis.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
129 |
4. Check minimum number of eventsNone |
129 |
5. Include endpointsNone |
129 |
6. Filter based on genotype QC (FinnGen only) |
120 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M46
- Name in latin
- Osteomyelitis vertebrae
Similar endpoints
↥List of similar endpoints to
Osteomyelitis of vertebra
based on the number of shared cases.
Similar with more cases:
- Autoimmune diseases related-to ILD
- Spondylopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 937 | 363 | 565 |
| Only index persons | 806 | 323 | 483 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 63.49 | 65.55 | 62.11 |
| Only index persons | 62.54 | 64.59 | 61.16 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 120 | 44 | 76 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.03 |
| Median age at first event (years) | 63.65 | 59.04 | 66.31 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 124
- Matched controls
- 1240
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M46.2
ICD-10 Finland
Osteomyelitis of vertebra
+∞
179.0
124
*
M46.3
ICD-10 Finland
Infection of intervertebral disc (pyogenic)
+∞
40.9
37
*
M46.4
ICD-10 Finland
Discitis, unspecified
+∞
39.7
36
*
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
231.5
34.7
34
*
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
64.8
32.8
37
8
M54.9
ICD-10 Finland
Dorsalgia, unspecified
12.7
29.0
32
33
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
29.9
26.2
35
16
J01MA12
ATC
levofloxacin; systemic
6.5
23.5
56
139
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
8.8
22.5
33
49
M48.0
ICD-10 Finland
Spinal stenosis
61.9
22.1
25
5
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
46.4
21.8
26
7
N03AX16
ATC
[U] pregabalin
6.6
21.5
45
98
N06AX21
ATC
duloxetine; oral
9.9
20.9
27
34
J01FF01
ATC
clindamycin; systemic
5.4
19.9
64
203
L28
ICPC
Limited function/disability (L)
5.8
18.2
44
108
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.9
17.8
41
96
M54.5
ICD-10 Finland
Low back pain
5.0
17.6
57
179
N02AX02
ATC
tramadol; systemic, rectal
4.9
17.3
77
309
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
8.4
17.2
25
36
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
31.2
16.2
21
8
J04AB02
ATC
rifampicin; systemic
97.7
16.0
17
*
M54.4
ICD-10 Finland
Lumbago with sciatica
6.8
15.6
28
51
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
8.1
15.4
23
34
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
+∞
14.9
14
*
N02AA05
ATC
oxycodone; systemic
4.7
14.8
46
137
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
60.7
14.2
16
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.6
14.1
90
450
A41.9
ICD-10 Finland
Sepsis, unspecified
13.9
14.0
24
21
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.5
13.3
43
131
UKC02
NOMESCO Finland
Cystoscopy
4.4
12.4
40
121
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.9
12.2
53
199
N03AX12
ATC
[U] gabapentin; oral
5.3
11.7
27
62
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
+∞
11.6
11
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.7
11.1
54
216
UJF32
NOMESCO Finland
Coloscopy
3.7
10.7
47
175
L03
ICPC
Low back symptom/complaint
3.8
10.5
43
153
ZXD05
NOMESCO Finland
Urgent procedure
3.4
10.3
56
239
J01CF05
ATC
flucloxacillin; systemic
5.9
10.2
20
39
X59
ICD-10 Finland
Exposure to unspecified factor
4.0
10.2
36
115
A46
ICD-10 Finland
Erysipelas
4.1
10.1
34
105
C03CA01
ATC
furosemide; systemic
3.3
9.6
58
261
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.3
9.5
53
227
G06.1
ICD-10 Finland
Intraspinal abscess and granuloma
+∞
9.5
9
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.7
9.4
19
38
TPH04
NOMESCO Finland
Cathetrisation of vein
3.5
9.3
41
152
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
26.3
9.1
12
5
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
53.9
8.8
10
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.4
8.7
40
151
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
29.9
8.6
11
*
SPAT1262
SPAT
Handing over of treatment supplies
3.6
8.6
35
122
A06AD11
ATC
lactulose; oral
3.9
8.6
29
89
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
96.3
8.5
9
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.3
8.5
44
179
NA1DG
NOMESCO Finland
Cervical spine very extensive MRI examination with high intensity magnet
+∞
8.4
8
*
I50.9
ICD-10 Finland
Heart failure, unspecified
3.5
8.4
35
124
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
3.0
8.4
63
317
N30.0
ICD-10 Finland
Acute cystitis
3.9
8.3
28
86
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
18.8
8.3
12
7
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.8
8.2
30
97
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
35.9
8.2
10
*
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
23.9
8.2
11
5
AA1AD
NOMESCO Finland
CT of head and brain
3.0
8.1
52
239
JN3AD
NOMESCO Finland
Abdominal CT examination
4.1
8.0
25
72
A40.8
ICD-10 Finland
Other streptococcal sepsis
16.4
7.9
12
8
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.8
7.8
28
89
J01XX08
ATC
linezolid; systemic
48.1
7.8
9
*
R51.80
ICD-10 Finland
Headache
3.7
7.7
28
90
SPAT1222
SPAT
Counselling/guidance promoting independent living
3.7
7.7
28
90
WX892
NOMESCO Finland
Monitored bed care
5.0
7.7
18
41
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
26.9
7.7
10
*
R50.9
ICD-10 Finland
Fever, unspecified
3.5
7.7
32
113
Z01.8
ICD-10 Finland
Other specified special examinations
3.3
7.6
35
131
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
85.0
7.5
8
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.9
7.4
25
76
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
4.7
7.3
18
43
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.4
7.3
30
105
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.6
7.1
27
89
ZXE00
NOMESCO Finland
One hour or less
2.7
7.0
59
308
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.9
7.0
43
190
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
4.4
7.0
19
49
J01CF02
ATC
cloxacillin; systemic
17.9
6.9
10
6
NA1AA
NOMESCO Finland
Cervical spine X-ray examination without contrast
17.9
6.9
10
6
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
42.4
6.8
8
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
8.6
6.8
14
18
N02BF01
ATC
gabapentin; oral
4.6
6.8
17
41
N17.9
ICD-10 Finland
Acute renal failure, unspecified
7.6
6.8
15
22
TK800
NOMESCO Finland
Hemodialysis
10.9
6.7
12
12
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.2
6.7
19
51
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
6.0
6.4
17
32
N05AH04
ATC
quetiapine; oral
3.3
6.4
28
101
205
Kela drug reimbursment
Chronic hypertension
2.7
6.4
47
227
J45
ICD-10 Finland
Asthma
4.4
6.4
17
43
M03BX02
ATC
tizanidine; oral
2.6
6.3
77
476
NA3CM
NOMESCO Finland
Lumbar spine extensive MRI examination with 3 Tesla magnet
+∞
6.3
6
*
NA3EA
NOMESCO Finland
Lumbar spine X-ray examination with flexion
+∞
6.3
6
*
7227C
ICD-9 Finland
Intervertebral disk disorders, Intervertebral disk disorder with myelopathy[SYNDROMA ISCHIADICUM]
+∞
6.3
6
*
N05BA04
ATC
oxazepam; oral
2.8
6.3
42
193
A28
ICPC
Limited function/disability NOS
3.0
6.3
33
133
C03DA01
ATC
spironolactone; oral
3.3
6.2
26
91
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
13.5
6.2
10
8
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.7
6.1
21
65
R31
ICD-10 Finland
Unspecified haematuria
3.5
6.0
23
76
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
30
56
6.75
16.36
7.4
3.3
2.44
2.76
mmol/l
0.14
23
44
24
39
7.39
14.82
2.2
2.4
—
—
—
0
0
22
35
7.43
13.80
6.0
3.1
24.42
25.58
mmol/l
0.38
22
35
21
20
12.39
11.82
11.7
6.4
13.99
9.81
mg/l
2.50
21
20
91
514
3.89
10.77
17.0
7.0
1.20
1.21
mmol/l
1.01
76
445
20
21
11.12
10.74
1.5
1.1
—
—
—
0
0
23
54
5.00
9.60
1.8
1.2
—
—
—
0
0
17
18
10.75
9.11
6.6
2.9
15.38
16.29
%
0.35
17
18
19
25
8.77
9.06
3.3
1.2
—
—
—
0
0
59
277
3.16
9.00
4.1
2.9
370.14
362.82
umol/l
0.18
50
243
26
74
4.18
8.52
2.2
1.5
—
—
—
0
0
34
119
3.56
8.30
8.4
2.9
—
—
—
0
0
19
29
7.53
8.28
6.7
2.6
7.45
7.72
kpa
0.20
19
29
27
81
3.98
8.23
4.8
3.4
1.19
1.23
mmol/l
2.46
27
68
56
267
3.00
8.15
3.4
2.0
3.17
2.90
mg/l
0.34
48
230
41
164
3.24
8.08
12.1
5.4
1.08
1.08
mmol/l
0.05
41
151
14
13
11.96
8.03
4.0
1.5
1.56
1.54
mmol/l
0.03
14
13
45
201
2.94
7.23
3.7
1.9
—
—
—
0
0
40
175
2.90
6.60
2.7
1.5
1267.94
1137.04
nmol/l
0.41
30
133
16
39
4.56
6.30
2.5
1.5
—
—
—
0
0
74
450
2.60
6.26
4.8
2.6
150.42
155.25
ug/l
0.09
69
417
89
597
2.74
6.07
18.5
10.9
4.39
4.24
e9/l
0.25
84
522
44
211
2.68
6.04
2.4
1.8
562.65
426.48
pmol/l
1.30
34
173
32
132
2.92
5.81
1.3
1.2
17.09
9.44
u/ml
—
10
54
14
25
6.17
5.56
2.4
1.7
—
—
—
0
0
69
426
2.40
5.38
3.3
2.4
73.19
76.49
nmol/l
0.38
61
374
72
453
2.41
5.38
2.4
2.0
94.88
92.83
pmol/l
0.11
36
240
67
409
2.39
5.35
8.0
4.0
46.26
36.43
ng/l
0.41
57
308
38
181
2.59
5.19
2.6
1.7
32.42
29.17
s
2.71
38
176
14
28
5.50
5.12
1.6
1.5
—
—
—
0
0
13
24
5.92
5.07
2.4
1.6
—
—
—
0
0
13
24
5.92
5.07
1.2
1.4
—
—
—
0
0
16
38
4.68
5.04
2.4
1.8
—
—
—
0
0
8
7
12.10
4.85
3.3
1.1
—
—
—
0
0
52
295
2.31
4.80
2.2
1.7
15.58
19.81
nmol/l
1.40
45
242
13
26
5.46
4.79
2.5
1.8
—
—
—
0
0
33
155
2.54
4.59
1.3
1.2
57.33
29.57
iu/ml
—
9
52
12
24
5.42
4.45
1.1
2.1
—
—
—
0
0
12
24
5.42
4.45
2.6
1.5
—
—
—
0
0
13
29
4.88
4.39
2.5
1.6
—
—
—
0
0
9
13
7.37
4.24
1.2
1.5
—
—
—
0
0
68
449
2.14
4.16
4.6
2.8
—
—
estimate
—
0
0
14
43
3.54
4.04
3.2
2.0
—
—
—
0
0
10
19
5.62
3.92
2.9
1.4
—
—
—
0
0
27
124
2.51
3.90
10.1
7.4
-0.04
1.13
mmol/l
0.44
22
108
56
351
2.09
3.85
6.2
3.7
3603.37
1478.26
ng/l
0.96
49
303
14
39
3.91
3.85
4.2
2.5
1.61
3.08
ratio
—
9
18
11
24
4.92
3.85
1.7
1.5
—
—
—
0
0
22
92
2.69
3.82
2.7
2.6
0.56
0.24
e6/l
0.64
22
86
14
40
3.81
3.75
2.9
1.8
—
—
—
0
0
7
9
8.16
3.61
3.7
1.2
—
—
—
0
0
9
17
5.62
3.58
1.8
1.2
—
—
—
0
0
9
17
5.62
3.58
3.1
1.2
—
—
—
0
0
10
23
4.63
3.39
1.0
1.2
284.00
399.00
u/ml
—
5
10
6
7
8.93
3.30
4.0
1.1
—
—
—
0
0
6
7
8.93
3.30
4.0
1.3
—
—
—
0
0
6
8
7.81
3.09
2.2
1.8
—
—
—
0
0
48
304
1.94
3.07
7.4
3.3
0.00
0.27
estimate
0.49
22
92
10
26
4.09
3.05
1.0
1.2
—
—
—
0
0
9
22
4.33
2.94
1.3
3.1
4.36
9.59
pmol/l
—
9
22
28
149
2.14
2.86
3.7
1.8
—
—
—
0
0
5
6
8.61
2.77
1.2
1.3
96.20
75.17
u/l
—
5
6
5
6
8.61
2.77
1.4
1.0
174.00
92.57
iu/ml
—
5
6
5
6
8.61
2.77
1.2
1.3
48.00
13.67
u/l
—
5
6
72
533
1.84
2.75
6.7
3.6
0.00
0.00
estimate
-0.00
26
112
6
10
6.24
2.73
1.0
1.6
5.55
4.69
mg/l
—
6
10
8
19
4.42
2.73
2.4
1.1
—
—
—
0
0
72
537
1.81
2.65
6.9
3.6
0.00
0.00
estimate
-0.00
29
113
46
301
1.84
2.59
7.0
3.6
0.00
0.02
estimate
0.50
24
108
5
7
7.38
2.57
1.0
1.1
—
—
—
0
0
5
7
7.38
2.57
1.0
1.4
1.89
2.09
mmol/l
—
5
7
72
543
1.78
2.50
6.8
3.6
0.00
2.94
estimate
0.50
28
102
39
245
1.86
2.49
4.2
2.4
—
—
—
0
0
26
142
2.05
2.47
3.8
1.8
—
—
—
0
0
89
718
1.85
2.43
4.4
3.7
15.00
14.95
pmol/l
0.06
79
634
8
22
3.81
2.41
1.4
1.3
—
—
—
0
0
16
73
2.37
2.33
11.1
9.7
93.08
93.12
%
0.01
16
73
73
568
1.69
2.14
3.5
2.8
—
—
—
0
0
15
70
2.30
2.08
3.0
1.6
—
—
—
0
0
35
227
1.75
1.97
4.8
3.3
930.37
335.79
ng/l
0.47
27
184
5
11
4.69
1.96
1.4
1.8
—
—
—
0
0
5
11
4.69
1.96
1.4
1.8
—
—
—
0
0
5
11
4.69
1.96
1.4
1.8
—
—
—
0
0
5
11
4.69
1.96
2.2
2.7
2.74
-0.27
mmol/l
—
5
11
5
11
4.69
1.96
1.4
1.8
—
—
—
0
0
5
12
4.29
1.84
1.4
1.8
—
—
—
0
0
5
12
4.29
1.84
1.4
1.8
—
—
—
0
0
8
29
2.88
1.82
1.1
1.3
—
—
—
0
0
111
994
2.11
1.80
59.2
15.3
29.45
26.36
mg/l
0.48
104
814
6
18
3.45
1.77
1.3
2.3
—
—
—
0
0
6
18
3.45
1.77
1.3
2.3
—
—
—
0
0
55
414
1.59
1.73
7.2
3.6
0.05
0.03
estimate
0.10
22
98
103
910
1.78
1.60
5.8
4.7
2.20
1.99
mu/l
0.62
92
814
31
208
1.65
1.53
1.4
1.3
1.31
0.79
u/ml
—
9
53
5
16
3.21
1.45
6.4
2.6
1.26
1.21
mmol/l
—
5
16
5
16
3.21
1.45
6.4
2.6
107.20
104.81
mmol/l
—
5
16
47
372
1.42
1.07
6.8
4.3
37.81
11.07
mg/mmol
1.23
34
249
11
60
1.91
1.06
5.0
2.9
1.33
1.32
%
0.01
11
60
51
416
1.38
0.96
2.2
2.0
1.57
1.36
mmol/l
0.94
41
331
59
498
1.35
0.88
5.1
5.5
1.58
3.08
ug/l
1.37
51
449
112
1053
1.66
0.87
60.0
18.3
139.26
139.59
mmol/l
0.82
112
1026
112
1053
1.66
0.87
61.1
18.5
4.06
3.99
mmol/l
1.94
112
1025
13
81
1.68
0.85
3.2
2.5
6.34
9.79
ug/l
0.45
13
74
6
32
1.92
0.83
1.5
1.4
—
—
—
0
0
10
59
1.76
0.78
4.2
2.7
0.58
0.58
%
—
10
59
9
53
1.75
0.77
2.6
2.8
4.23
4.36
pmol/l
—
9
47
5
24
2.13
0.75
2.0
1.1
—
—
—
0
0
106
994
1.46
0.72
45.7
15.4
75.47
78.70
ml/min/173m2
0.60
100
906
24
182
1.40
0.68
5.5
2.7
2.28
1.00
e6/l
0.64
19
101
5
29
1.75
0.64
1.0
1.7
—
—
—
0
0
12
80
1.55
0.62
2.9
3.8
48.50
54.50
ml/min/173m2
—
6
36
113
1082
1.50
0.57
62.7
20.6
105.29
82.05
umol/l
1.69
113
1064
114
1102
1.43
0.43
72.7
23.8
4.19
4.52
e12/l
6.91
114
1066
114
1102
1.43
0.43
73.3
23.8
252.03
238.39
e9/l
0.97
114
1072
114
1102
1.43
0.43
73.5
23.9
125.81
136.28
g/l
8.10
114
1085
114
1102
1.43
0.43
72.4
23.7
91.97
91.20
fl
0.81
114
1086
7
57
1.24
0.29
1.6
2.2
—
—
—
0
0
9
118
0.74
0.29
7.3
7.5
—
—
—
0
0
26
294
0.85
0.25
2.6
3.2
0.64
0.84
ug/l
1.06
18
197
102
988
1.18
0.24
6.4
5.1
6.34
6.04
mmol/l
0.90
89
890
5
38
1.33
0.23
1.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
237.16
—
0
10
99
961
1.15
0.20
9.7
6.8
42.15
39.88
mmol/mol
1.11
91
898
0
14
0.00
0.20
0.0
1.1
—
7.68
—
0
9
7
62
1.14
0.17
1.3
2.5
—
—
—
0
0
99
965
1.13
0.16
5.2
4.4
1.34
1.27
mmol/l
0.53
88
877
42
397
1.09
0.13
2.8
4.5
22.80
22.37
%
0.07
22
203
16
144
1.13
0.11
1.3
1.5
—
—
—
0
0
8
78
1.03
0.07
1.5
1.4
—
—
—
0
0
103
1032
0.99
0.00
6.8
5.8
2.36
2.63
mmol/l
2.38
91
941
101
1011
0.99
0.00
6.4
5.1
4.20
4.51
mmol/l
2.20
91
929
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
5
0.00
-0.00
0.0
1.0
—
120.40
—
0
5
0
7
0.00
-0.00
0.0
2.7
—
78.57
—
0
7
101
1010
1.00
-0.00
6.2
5.1
1.32
1.43
mmol/l
1.90
90
919
0
7
0.00
-0.00
0.0
2.9
—
1002.29
—
0
7
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
90
1.00
-0.00
1.9
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_OSTEOMYELVERTEB and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_OSTEOMYELVERTEB | 1.996 [1.5, 2.65] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.024 |
During the follow-up period (1.1.1998 — 31.12.2019), 121 out of 325 females with M13_OSTEOMYELVERTEB died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_OSTEOMYELVERTEB | 2.433 [1.84, 3.22] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 201 out of 503 males with M13_OSTEOMYELVERTEB died.
Mortality risk
Mortality risk for people of age
years, who have M13_OSTEOMYELVERTEB.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.15% | 0.363% |
| 5 | 0.982% | 2.718% |
| 10 | 2.528% | 6.78% |
| 15 | 4.728% | 12.398% |
| 20 | 8.398% | 20.461% |
Relationships between endpoints
↥Index endpoint: M13_OSTEOMYELVERTEB – Osteomyelitis of vertebra
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data